Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 53 clinical trials
Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML

most important adverse prognostic factors for AML, and older patients are unable to tolerate high-dose chemotherapy, due to various complications and organ dysfunction. Based on the results of the

remission
consolidation therapy
umbilical cord blood transplantation
decitabine
cytarabine
  • 0 views
  • 03 Feb, 2022
  • 1 location
Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients

High dose chemotherapy and radiation used as preparative regimens in patients undergoing an allogeneic hematopoietic stem cell transplant (HSCT) disrupts intestinal homeostasis by damaging the

graft versus host disease
bone marrow transplant
acute graft-versus-host disease
allogeneic hematopoietic stem cell transplant
  • 0 views
  • 13 Jun, 2022
  • 1 location
Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases

which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a

peripheral neuropathy
spinal cord
neuromyelitis optica
antithymocyte globulin
ataxia
  • 213 views
  • 01 Jul, 2022
  • 3 locations
Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation

-dose chemotherapy and/or radiation-related toxicity. Parenteral nutrition (PN) with lipid emulsion is commonly required while gastrointestinal complications preclude adequate oral or enteral intake. PN

cancer
hematologic malignancy
fish oil
busulfan
transplant conditioning
  • 8 views
  • 29 Jun, 2022
  • 1 location
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side

carboplatin
brain tumor
cancer chemotherapy
neutrophil count
platelet count
  • 0 views
  • 27 Jun, 2022
  • 31 locations
Autologous Stem Cell Transplant for Crohn's Disease

undergo stem cell transplant which will involve high dose chemotherapy and require a 2-4 week hospitalization. After restoration of the immune system patients will be placed on vedolizumab per standard

endoscopy
golimumab
ustekinumab
corticosteroids
mercaptopurine
  • 66 views
  • 25 Jan, 2021
  • 1 location
Reduced Intensity Transplantation for Severe Sickle Cell Disease

This study is being done to test a transplant method that may have fewer side effects (or less toxic, less harmful) than conventional high dose chemotherapy conditioning-based transplants for

acute chest syndrome
alemtuzumab
sirolimus
hemoglobinopathy
transcranial doppler ultrasonography
  • 0 views
  • 29 May, 2022
  • 1 location
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

This is a multicentric single arm phase II trial, to investigate the efficacy (in terms of PFS) of the combination regimen rituximab-bendamustine in association with copanlisib in patients affected by relapsed/refractory DLBCL, not eligible to HDC and ASCT or relapsed after intensified regimens.

  • 0 views
  • 16 May, 2022
  • 12 locations
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.

graft-versus-host disease
preparative regimen
campath
mycophenolate mofetil
transplant conditioning
  • 142 views
  • 24 Jan, 2022
  • 20 locations
Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

This is a phase 2, open-label, multicenter study evaluating axicabtagene ciloleucel (axi-cel) as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible to receive Autologous Stem Cell Transplantation but eligible to receive CAR T-cell therapy.

  • 0 views
  • 06 May, 2022
  • 16 locations